Middle East Tech Today
SEE OTHER BRANDS

The best science and technology news from the Middle East

Middle East Tech Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East Tech Today.

Press releases published on May 8, 2025

Rumble Reports First Quarter 2025 Results

Rumble Reports First Quarter 2025 Results

~ Revenue up 34% Year-over-Year to $23.7 Million ~ ~ Rumble Cloud Secures Contract with Government of El Salvador ~ ~ Significantly Improved MAU Retention Compared to 2022 Mid-Term Elections ~ ~ Tether Investment Completed, Balance Sheet Solidified ~ …

AvePoint Announces First Quarter 2025 Financial Results

AvePoint Announces First Quarter 2025 Financial Results

First quarter SaaS revenue of $68.9 million, representing 34% year-over-year growth, 37% on a constant currency basis First quarter Total revenue of $93.1 million, representing 25% year-over-year growth, 27% on a constant currency basis Total ARR of $345.5 …

Fulcrum Therapeutics to Participate in Upcoming May Conferences

Fulcrum Therapeutics to Participate in Upcoming May Conferences

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …

Cytek Biosciences Reports First Quarter 2025 Financial Results

Cytek Biosciences Reports First Quarter 2025 Financial Results

FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First …

Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates

Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates

Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with …

IBEX Reports Record Quarterly Revenue and EPS, Returns to Double-Digit Growth, Raises Fiscal Year Guidance

IBEX Reports Record Quarterly Revenue and EPS, Returns to Double-Digit Growth, Raises Fiscal Year Guidance

Quarterly revenue grew 11% versus prior year quarter - highest growth in ten quarters Adjusted EPS of $0.82 - an increase of 18% to prior year quarter Makes strategic entry into India - launching with leading healthcare client Board authorizes a new $15 …

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data …

Lantronix Reports Results for Third Quarter of Fiscal 2025

Lantronix Reports Results for Third Quarter of Fiscal 2025

Third Quarter Net Revenue of $28.5 Million Third Quarter GAAP EPS of ($0.10) Third Quarter Non-GAAP EPS of $0.03 IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for the Internet of …

TELA Bio Reports First Quarter 2025 Financial Results

TELA Bio Reports First Quarter 2025 Financial Results

MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended …

CEA Industries Inc. Provides Update on Fat Panda Acquisition 

CEA Industries Inc. Provides Update on Fat Panda Acquisition 

Transaction reflects CEA Industries’ strategic evolution and pivotal entry into attractive high-growth vape market Accelerates Fat Panda’s growth initiatives as central Canada’s largest retailer and manufacturer of e-cigarettes, vape devices and e-liquids …

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering …

Synaptics Reports Third Quarter Fiscal 2025 Results

Synaptics Reports Third Quarter Fiscal 2025 Results

Quarterly revenues increased 12% year-over-year, driven by a 43% growth in Core IoT product sales Q3’25 Financial Results Revenue of $266.6 million GAAP gross margin of 43.4% Non-GAAP gross margin of 53.5% GAAP loss per share of $0.56 Non-GAAP diluted …

Snail, Inc. Sets First Quarter 2025 Conference Call for Wednesday, May 14, 2025 at 4:30 p.m. ET

Snail, Inc. Sets First Quarter 2025 Conference Call for Wednesday, May 14, 2025 at 4:30 p.m. ET

CULVER CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, will hold a conference call and webcast on …

Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025

Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2025

FRAMINGHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended March …

SIGA Reports Financial Results for Three Months Ended March 31, 2025

SIGA Reports Financial Results for Three Months Ended March 31, 2025

Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March $94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025 Corporate Update Conference Call Today at 4:30 PM ET NEW …

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025

REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data from its …

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials …

NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025

NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025

TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system …

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of …

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025

1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service